Literature DB >> 23374737

Bone turnover markers in primary hyperparathyroidism.

Aline G Costa1, John P Bilezikian.   

Abstract

Primary hyperparathyroidism is an endocrine disorder characterized by elevated or inappropriate normal levels of parathyroid hormone in a setting of hypercalcemia. The inclusion of calcium on the basic metabolic bone panel has allowed this disorder to be diagnosed even in the absence of symptoms. Nevertheless, the skeleton can be a target of excess parathyroid hormone activity even during its asymptomatic presentation. Bone turnover markers a surrogate index of the process of the remodeling process at the level of bone, and thus can be useful to monitor skeleton involvement in primary hyperparathyroidism.
Copyright © 2013 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23374737      PMCID: PMC3577420          DOI: 10.1016/j.jocd.2012.11.004

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  52 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

2.  Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.

Authors:  A H van Lierop; J E Witteveen; N A T Hamdy; S E Papapoulos
Journal:  Eur J Endocrinol       Date:  2010-09-03       Impact factor: 6.664

3.  Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.

Authors:  Carola Krause; Olexandr Korchynskyi; Karien de Rooij; Stella E Weidauer; David J J de Gorter; Rutger L van Bezooijen; Sarah Hatsell; Aris N Economides; Thomas D Mueller; Clemens W G M Löwik; Peter ten Dijke
Journal:  J Biol Chem       Date:  2010-10-15       Impact factor: 5.157

4.  Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Authors:  Munro Peacock; J P Bilezikian; M A Bolognese; Michael Borofsky; Simona Scumpia; L R Sterling; Sunfa Cheng; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

5.  Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy.

Authors:  Philippe Boudou; Fidaa Ibrahim; Catherine Cormier; Emile Sarfati; Jean-Claude Souberbielle
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

6.  Alendronate therapy in men with primary hyperparathyroidism.

Authors:  Aliya A Khan; John P Bilezikian; Annie Kung; Sacha J Dubois; Timothy I Standish; Zeba A Syed
Journal:  Endocr Pract       Date:  2009 Nov-Dec       Impact factor: 3.443

7.  Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Authors:  Pedro Iglesias; Guillermo Ais; Ana González; Pilar Tajada; Carmen García Arévalo; Enrique Fernández Pardo; Juan J Díez
Journal:  Am J Med Sci       Date:  2008-02       Impact factor: 2.378

8.  The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.

Authors:  Mishaela R Rubin; John P Bilezikian; Donald J McMahon; Thomas Jacobs; Elizabeth Shane; Ethel Siris; Julia Udesky; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

9.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

10.  Cinacalcet for the treatment of primary hyperparathyroidism.

Authors:  Saima Sajid-Crockett; Frederick R Singer; Jerome M Hershman
Journal:  Metabolism       Date:  2008-04       Impact factor: 8.694

View more
  10 in total

1.  Polymorphisms of the vitamin D receptor and their effect on bone mass density in patients with normocalcemic hyperparathyroidism.

Authors:  Jose Luis Perez Castrillón; Gonzalo Díaz-Soto; Olatz Izaola Jauregui; Enrique Romero; Daniel de Luis Román
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

2.  Changes in bone turnover markers in primary hyperparathyroidism and response to surgery.

Authors:  P Rajeev; A Movseysan; A Baharani
Journal:  Ann R Coll Surg Engl       Date:  2017-09       Impact factor: 1.891

Review 3.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

4.  Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density.

Authors:  M Li; F Lv; Z Zhang; W Deng; Y Li; Z Deng; Y Jiang; O Wang; X Xing; L Xu; W Xia
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

5.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

Review 6.  Parathyroid Pathology.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-27

7.  Laboratory aspects and clinical utility of bone turnover markers.

Authors:  Harjit Pal Bhattoa
Journal:  EJIFCC       Date:  2018-07-11

8.  Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population.

Authors:  Su-Min Jeong; Dong Wook Shin; Ji Eun Lee; Sang-Man Jin; Sung Kim
Journal:  Cancer Res Treat       Date:  2018-06-27       Impact factor: 4.679

9.  Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.

Authors:  Wenjing Ni; Yue Yuan; Xiaoqiu Chu; Guofang Chen; Xue Han; Jie Li; Xinping Wu; Jianhua Wang; Chao Liu; Shuhang Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-01       Impact factor: 5.555

10.  Bone turnover and bone mineral density in old persons with type 2 diabetes.

Authors:  João Martin Martins; Patrícia Aranha
Journal:  J Clin Transl Endocrinol       Date:  2018-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.